This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Naproxcinod
DrugBank Accession Number
DB06682
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 347.367
Monoisotopic: 347.1368874
Chemical Formula
C18H21NO6
Synonyms
  • (S)-2-(6-Methoxy-2-naphthyl)propanoic acid 4-nitrooxybutyl ester
  • Naproxcinod
  • Naproxcinodum
  • Naproxen-N-butyl nitrate
External IDs
  • AR-P900758XX
  • AZD 3582
  • AZD-3582
  • AZD3582
  • HCT 3012
  • HCT-3012

Pharmacology

Indication

Investigated for use/treatment in pain (acute or chronic), inflammatory disorders (unspecified), osteoarthritis, and arthritis and arthritic pain.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

ATC Codes
M01AE18 — Naproxcinod
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Anisoles / Alkyl aryl ethers / Alkyl nitrates / Organic nitro compounds / Organic nitric acids and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives
show 1 more
Substituents
Alkyl aryl ether / Alkyl nitrate / Allyl-type 1,3-dipolar organic compound / Anisole / Aromatic homopolycyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Ether / Hydrocarbon derivative
show 10 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
carboxylic ester, methoxynaphthalene, nitrate ester (CHEBI:76254)
Affected organisms
Not Available

Chemical Identifiers

UNII
V24GR4LI3I
CAS number
163133-43-5
InChI Key
AKFJWRDCWYYTIG-ZDUSSCGKSA-N
InChI
InChI=1S/C18H21NO6/c1-13(18(20)24-9-3-4-10-25-19(21)22)14-5-6-16-12-17(23-2)8-7-15(16)11-14/h5-8,11-13H,3-4,9-10H2,1-2H3/t13-/m0/s1
IUPAC Name
4-(nitrooxy)butyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
SMILES
COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCCCO[N+]([O-])=O

References

General References
Not Available
KEGG Drug
D09568
ChemSpider
8060316
ChEBI
76254
ChEMBL
CHEMBL2103831
ZINC
ZINC000001541804
Wikipedia
Naproxcinod

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentOsteoarthritis (OA)2
3CompletedTreatmentOsteoarthritis (OA) / Osteoarthritis in the Hip Joint1
2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
1CompletedBasic ScienceLiver Disease1
1CompletedBasic SciencePharmacokinetics1
1CompletedBasic ScienceRenal Hemodynamics1
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Osteoarthritis (OA)2
1CompletedTreatmentKidney Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000281 mg/mLALOGPS
logP3.79ALOGPS
logP3.72ChemAxon
logS-6.1ALOGPS
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area87.9 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity91.11 m3·mol-1ChemAxon
Polarizability36.19 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at March 19, 2008 16:48 / Updated at June 12, 2020 16:52